You are here: Home / Research / Research Faculty / indrieri

Alessia Indrieri

Assistant Investigator, TIGEM

Tenured Researcher, Institute for Genetic and Biomedical Research (IRGB), CNR, Milan, Italy

Targeting mitochondria to treat rare and common neurodegenerative disorders

Mitochondrial dysfunction underlies the pathogenesis of a variety of human neurodegenerative diseases (ND), either directly, in the case of the rare Mitochondrial Diseases (MDs), or indirectly, as in more common ND, such as Parkinson and Alzheimer diseases.
In particular a tight connection between vision and mitochondrial dysfunction has been extensively described. Several MDs are associated with some form of vision impairment. In particular Leber Hereditary Optic Neuropathy (LHON) and Autosomal Dominant Optic Atrophy (ADOA), the most frequent mitochondrial optic neuropathies, are both characterized by degeneration of retinal ganglion cells and loss of vision. Interestingly, also the most common optic neuropathies such as glaucoma and diabetic retinopathy show signs of mitochondrial dysfunction and share clinical similarities with the hereditary MDs.
Despite a vast amount of research these pathologies are still only treated symptomatically, and, in this respect, mitochondria could represent the common denominator and hence a promising therapeutic target.
We recently demonstrated that the microRNAs miR-181a and miR-181b (miR-181a/b) regulate key genes involved in mitochondrial biogenesis function and clearance. We also show that these miRNAs are involved in the global regulation of mitochondrial turnover in the central nervous system (CNS) through the coordination of mitochondrial biogenesis and mitophagy. Interestingly miR-181a/b downregulation protects neurons from cell death and ameliorates the disease phenotype in different in vivo models of MDs, including LHON.

The main interest of the lab is to develop and validate new therapeutic strategies enhancing mitochondrial turnover in the CNS to treat mitochondrial-associated neurodegeneration in a mutation-independent manner. Our strategies will be applied in models of rare diseases such as mitochondrial optic neuropathies, as well as in model of common disorders such as glaucoma, diabetic retinopathy and Parkinson disease.

Indrieri A, Carrella S, Carotenuto P, Banfi S, Franco B. The Pervasive Role of the Mir-181 Family in Development, Neurodegeneration, and Cancer. Int J Mol Sci. 2020 Mar 18;21(6):2092. doi: 10.3390/ijms21062092.

Indrieri A, Carrella S, Romano A, Spaziano A, Marrocco E, Fernandez-Vizarra E, Barbato S, Pizzo M, Ezhova Y, Golia FM, Ciampi L, Tammaro R, Henao-Mejia J, Williams A, Flavell RA, De Leonibus E, Zeviani M, Surace EM, Banfi S, Franco B. Mir-181a/B Downregulation Exerts a Protective Action on Mitochondrial Disease Models. EMBO Mol Med. 2019 May;11(5):e8734. doi: 10.15252/emmm.201708734.

Indrieri A, Grimaldi C, Zucchelli S, Tammaro R, Giustincich S, Franco B. Synthetic Long Non-Coding Rnas [Sineups] Rescue Defective Gene Expression in Vivo. Sci Rep. 2016 Jun 6;6:27315. doi: 10.1038/srep27315.

Indrieri A, Conte I, Chesi G, Romano A, Quartararo J, Tate R, Ghezzi D, Zeviani M, Goffrini P, Ferrero I, Bovolenta P, Franco B. The Impairment of Hccs Leads to Mls Syndrome by Activating a Non-Canonical Cell Death Pathway in the Brain and Eyes. EMBO Mol Med
. 2013 Feb;5(2):280-93. doi: 10.1002/emmm.201201739. Epub 2013 Jan 22.

Indrieri A, van Rahden VA, Tiranti V, Morleo M, Iaconis D, Tammaro R, D'Amato I, Conte I, Maystadt I, Demuth S, Zvulunov A, Kutsche K, Zeviani M, Franco B. Mutations in Cox7b Cause Microphthalmia with Linear Skin Lesions, an Unconventional Mitochondrial Disease. Am J Hum Genet. 2012 Nov 2;91(5):942-9. doi: 10.1016/j.ajhg.2012.09.016.

Alessia Indrieri PHD

Molecular Therapy

Office: +3908119230683
Fax: +3908119230651